{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=108",
    "query": {
      "intervention": "Dose Level 3",
      "page": 108
    },
    "page_size": 10
  },
  "pagination": {
    "page": 108,
    "page_size": 10,
    "total_count": 17854,
    "total_pages": 1786,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=109&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=107&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T07:21:22.676Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05405309",
      "title": "RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "RP-3500",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-09-23",
      "completion_date": "2025-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405309"
    },
    {
      "nct_id": "NCT00270699",
      "title": "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "rDEN4delta30-200,201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2006-06",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00270699"
    },
    {
      "nct_id": "NCT05919693",
      "title": "A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration (NVAMD)",
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "Remigromig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-06-12",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05919693"
    },
    {
      "nct_id": "NCT05040776",
      "title": "COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombopenia",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "EP-7041 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "eXIthera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-10",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05040776"
    },
    {
      "nct_id": "NCT06655376",
      "title": "Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bleeding",
        "Clot Blood"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2024-10-02",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06655376"
    },
    {
      "nct_id": "NCT00062868",
      "title": "LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Non Hodgkin Lymphoma",
        "Lymphoepithelioma",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "LMP1/2 CTLs (ALCI - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group C)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 74,
      "start_date": "2003-09",
      "completion_date": "2020-04",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062868"
    },
    {
      "nct_id": "NCT05943535",
      "title": "Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Progressive Pulmonary Fibrosis",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Treprostinil Ultrasonic Nebulizer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 698,
      "start_date": "2023-10-30",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05943535"
    },
    {
      "nct_id": "NCT04969276",
      "title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Inactivated Influenza High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 mRNA Vaccine (nucleoside modified)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2021-07-16",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 6,
      "location_summary": "Glendale, Arizona • San Diego, California • Vista, California + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969276"
    },
    {
      "nct_id": "NCT01104376",
      "title": "Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Efavirenz, Metabolism and Pharmacokinetics Changes"
      ],
      "interventions": [
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 61,
      "start_date": "2010-03",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-12-17",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01104376"
    },
    {
      "nct_id": "NCT01499017",
      "title": "A Single Dose Study Of PF-06291874 In Healthy Adult Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06291874 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-11",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-31",
      "last_synced_at": "2026-11-22T07:21:22.676Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499017"
    }
  ]
}